30% of diabetic patients will eventually develop diabetic nephropathy Studies have shown that close to 30% of diabetic patients will eventually develop diabetic nephropathy, and some will go on to develop uremia. The proportion of patients with end-stage renal disease caused by diabetes is gradually increasing, and diabetic nephropathy has become the most important cause of end-stage renal disease in some developed countries, and ranks second in China. For diabetic patients, radical resection of one kidney is like adding insult to injury, and the incidence of renal insufficiency increases significantly, which increases the possibility of needing dialysis treatment or kidney transplantation. Kidney cancer does not always require radical nephrectomy Kidney cancer, also known as renal cell carcinoma, is the most common malignant tumor in adult kidney, and its incidence accounts for about 2%-3% of adult malignant tumors, and is the second most common malignant tumor in the urinary system, second only to bladder cancer. According to statistics, the incidence of renal cell carcinoma is increasing at a rate of 2% per year worldwide, and the reasons for the increase in incidence are still unclear. With the rapid development of tumor imaging, especially with the continuous development of multi-layer spiral CT, the early diagnosis rate of kidney cancer has been greatly improved. At present, surgical resection is still the most effective means to treat limited renal cell carcinoma. For stage T1 renal cancer (≤7 cm in diameter), kidney unit preservation surgery (NSS) is a reasonable surgical approach for the treatment of renal cancer, which can preserve renal function to the maximum extent. Partial nephrectomy has achieved the same therapeutic results as radical nephrectomy, and the overall survival rate is better than that of radical surgery. The incidence of renal insufficiency after radical surgery was exclusively partial nephrectomy (22.4% vs. 11.6%). The study showed that the 5-year tumor-specific survival rate of elective partial nephrectomy ranged from 94.4% to 100%, and the 10-year tumor-specific survival rate ranged from 92% to 96.7%.